TransMedics Group, Inc.
TMDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $3 | $2 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $1 | $1 | $0 | $0 |
| Enterprise Value | $2 | $3 | $2 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 82.7% | 158.5% | 208.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 59.4% | 63.8% | 69.8% | 69.9% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 15.8% | -3.2% | -31% | -127.2% |
| Net Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 8% | -10.4% | -38.8% | -146.1% |
| EPS Diluted | 1.01 | -0.77 | -1.23 | -1.6 |
| % Growth | 231.2% | 37.4% | 23.1% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |